Biomarkers and Gene Signatures to Predict Durable Response to Pembrolizumab in Non-Small Cell Lung Cancer

SIMPLE SUMMARY: Not all patients with advanced or metastatic non-small cell lung cancer (NSCLC) respond to pembrolizumab, even if their tumor expresses PD-L1. This is a monocentric study aimed at identifying potential predictive biomarkers for pembrolizumab first-line treatment. Tumor microenvironme...

Descripción completa

Detalles Bibliográficos
Autores principales: Poma, Anello Marcello, Bruno, Rossella, Pietrini, Iacopo, Alì, Greta, Pasquini, Giulia, Proietti, Agnese, Vasile, Enrico, Cappelli, Sabrina, Chella, Antonio, Fontanini, Gabriella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345106/
https://www.ncbi.nlm.nih.gov/pubmed/34359727
http://dx.doi.org/10.3390/cancers13153828

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8345106/
https://www.ncbi.nlm.nih.gov/pubmed/34359727
http://dx.doi.org/10.3390/cancers13153828

Ejemplares similares